Alicyn Magruder

Oct 31, 2023 | neurologylive.com | Jeffrey Cohen |Sarah Anderson |Alicyn Magruder |Matt Hoffman

WATCH TIME: 12 minutesThe treatment paradigm for multiple sclerosis (MS) has come a long way since the early years of ABCR agents, with a therapeutic arsenal of disease-modifying therapies now numbering in the 20s. Yet, with all of the change that advances in pharmaceutical development have brought, there are still novel approaches being introduced—and perhaps the biggest recent introduction is biosimilars.

Oct 29, 2023 | neurologylive.com | Jeffrey Cohen |Sarah Anderson |Alicyn Magruder |Matt Hoffman

WATCH TIME: 9 minutesThe treatment paradigm for multiple sclerosis (MS) has come a long way since the early years of ABCR agents, with a therapeutic arsenal of disease-modifying therapies now numbering in the 20s. Yet, with all of the change that advances in pharmaceutical development have brought, there are still novel approaches being introduced—and perhaps the biggest recent introduction is biosimilars.

Oct 27, 2023 | neurologylive.com | Jeffrey Cohen |Sarah Anderson |Alicyn Magruder |Matt Hoffman

October 27, 2023Jeff Cohen, MD, and Alicyn Magruder, PharmD, BCACP, MSCS, discuss the best practices when switching to a biosimilar therapy, including patient education and when to consider an insurance appeal. [WATCH TIME: 7 minutes]WATCH TIME: 7 minutesThe treatment paradigm for multiple sclerosis (MS) has come a long way since the early years of ABCR agents, with a therapeutic arsenal of disease-modifying therapies now numbering in the 20s.

Oct 25, 2023 | neurologylive.com | Jeffrey A Cohen |Sarah Anderson |Alicyn Magruder |Matt Hoffman

October 25, 2023Alicyn Magruder, PharmD, BCACP, MSCS, offers insight into the pharmacist's role in patient education on biosimilars for MS, and the group discusses the potential need for a long-term monitoring system. [WATCH TIME: 10 minutes]WATCH TIME: 10 minutesThe treatment paradigm for multiple sclerosis (MS) has come a long way since the early years of ABCR agents, with a therapeutic arsenal of disease-modifying therapies now numbering in the 20s.

Oct 23, 2023 | neurologylive.com | Jeffrey A Cohen |Sarah Anderson |Alicyn Magruder |Matt Hoffman

WATCH TIME: 9 minutesThe treatment paradigm for multiple sclerosis (MS) has come a long way since the early years of ABCR agents, with a therapeutic arsenal of disease-modifying therapies now numbering in the 20s. Yet, with all of the change that advances in pharmaceutical development have brought, there are still novel approaches being introduced—and perhaps the biggest recent introduction is biosimilars.